VJHemOnc is committed to improving our service to you

EHA 2020 | Impact of ruxolitinib approval on myelofibrosis real-world survival in the US

VJHemOnc is committed to improving our service to you

Srdan Verstovsek

Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, outlines the impact of ruxolitinib’s approval in 2011 on real-world data of elderly myelofibrosis patients in the United States. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter